Boyu Hu, MD

Articles by Boyu Hu, MD

BTK Degraders and Other Targets in Mantle Cell Lymphoma

ByAlexey V. Danilov, MD, PhD,Bijal D. Shah, MD,Matthew J. Matasar, MD,Boyu Hu, MD

February 28th 2023

Experts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.

The Role of Bispecific Antibodies in Mantle Cell Lymphoma

ByAlexey V. Danilov, MD, PhD,Bijal D. Shah, MD,Matthew J. Matasar, MD,Boyu Hu, MD

February 21st 2023

A comprehensive look at the role of bispecific antibodies, including glofitamab, in the treatment of mantle cell lymphoma.

Treating Patients With MCL Who Progress on BTK Inhibitors

ByAlexey V. Danilov, MD, PhD,Bijal D. Shah, MD,Matthew J. Matasar, MD,Boyu Hu, MD

February 21st 2023

Bijal D. Shah, MD, and Matthew J. Matasar, MD, discuss how they approach treating patients with MCL who rapidly progress on BTK inhibitors.

CAR T-Cell Therapy in Patients With MCL: Clinical Trial and Real-World Data

ByAlexey V. Danilov, MD, PhD,Bijal D. Shah, MD,Matthew J. Matasar, MD,Boyu Hu, MD

February 14th 2023

A panel of experts in hematologic malignancies analyze clinical studies and real-world data of brexucabtagene autoleucel in mantle cell lymphoma.

Patient Profile 2: A 60-Year-Old Man With Mantle Cell Lymphoma

ByAlexey V. Danilov, MD, PhD,Bijal D. Shah, MD,Matthew J. Matasar, MD,Boyu Hu, MD

February 14th 2023

Alexey V. Danilov, MD, PhD, presents a second patient profile of a 60-year-old patient with MCL, and the panel discusses using CAR T-cell therapy to treat MCL.

Approaches to Treating Patients With High-Risk Mantle Cell Lymphoma

ByAlexey V. Danilov, MD, PhD,Bijal D. Shah, MD,Matthew J. Matasar, MD,Boyu Hu, MD

February 7th 2023

A comprehensive discussion on ways to approach treating patients with high-risk mantle cell lymphoma.

Selecting the Appropriate BTKi in MCL and Potential Role of Pirtobrutinib

ByAlexey V. Danilov, MD, PhD,Bijal D. Shah, MD,Matthew J. Matasar, MD,Boyu Hu, MD

February 7th 2023

A detailed look at how to select the appropriate BTK inhibitor to treat patients with MCL and the potential role of the non-covalent BTK inhibitor pirtobrutinib in MCL.

BTK Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma

ByAlexey V. Danilov, MD, PhD,Bijal D. Shah, MD,Matthew J. Matasar, MD,Boyu Hu, MD

January 31st 2023

Experts in hematologic malignancies review the role of BTK inhibitors and other therapies in patients with relapsed/refractory mantle cell lymphoma.

SHINE Study: Ibrutinib Plus Bendamustine and Rituximab in Elderly Patients With MCL

ByAlexey V. Danilov, MD, PhD,Bijal D. Shah, MD,Matthew J. Matasar, MD,Boyu Hu, MD

January 31st 2023

A panel of experts in hematologic malignancies discuss the SHINE study, which looked at ibrutinib with bendamustine and rituximab in elderly patients with MCL.

Is There a Role for Response-Adapted Treatment in Mantle Cell Lymphoma?

ByAlexey V. Danilov, MD, PhD,Bijal D. Shah, MD,Matthew J. Matasar, MD,Boyu Hu, MD

January 24th 2023

Matthew J. Matasar, MD, discusses the prospect of using minimal residual disease to guide treatment decisions in mantle cell lymphoma.

TRIANGLE Study: Ibrutinib vs Stem Cell Transplant in Younger Patients With MCL

ByAlexey V. Danilov, MD, PhD,Bijal D. Shah, MD,Matthew J. Matasar, MD,Boyu Hu, MD

January 24th 2023

Boyu Hu, MD, and Bijal D. Shah, MD, provide their thoughts on the TRIANGLE study looking at ibrutinib versus stem cell transplant in MCL.

Patient Profile 1: A 74-Year-Old Man Diagnosed With Mantle Cell Lymphoma

ByAlexey V. Danilov, MD, PhD,Bijal D. Shah, MD,Matthew J. Matasar, MD,Boyu Hu, MD

January 17th 2023

A patient profile of a 74-year-old man diagnosed with mantle cell lymphoma who receives treatment with a non-covalent BTK inhibitor is presented by Alexey V. Danilov, MD, PhD.